Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien

C Scheifele; H Schlechte; G Bethke; P A Reichart

doi:10.1007/s10006-002-0425-0

Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien

Standard

Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien. / Scheifele, C; Schlechte, H; Bethke, G; Reichart, P A.

in: Mund Kiefer Gesichtschir, Jahrgang 6, Nr. 6, 01.11.2002, S. 410-4.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Scheifele, C, Schlechte, H, Bethke, G & Reichart, PA 2002, 'Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien', Mund Kiefer Gesichtschir, Jg. 6, Nr. 6, S. 410-4. https://doi.org/10.1007/s10006-002-0425-0

APA

Scheifele, C., Schlechte, H., Bethke, G., & Reichart, P. A. (2002). Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien. Mund Kiefer Gesichtschir, 6(6), 410-4. https://doi.org/10.1007/s10006-002-0425-0

Vancouver

Scheifele C, Schlechte H, Bethke G, Reichart PA. Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien. Mund Kiefer Gesichtschir. 2002 Nov 1;6(6):410-4. https://doi.org/10.1007/s10006-002-0425-0

Bibtex

@article{a6462ba8e2e3487d8e6893c4cde6a2cc,

title = "Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien",

abstract = "OBJECTIVE: The aim of this study was to determine the prevalence of mutations of the tumour suppressor gene TP53 in oral leukoplakias.MATERIAL AND METHOD: Brush biopsy specimens of 43 oral leukoplakias, 26 oral squamous cell carcinomas (OSCC) for reference, and the oral mucosa of 4 clinically normal volunteers were collected. DNA of the critical exons 5-8 was analysed by temperature gradient gel electrophoresis (TGGE).RESULTS: The prevalence of mutations was 57.7% in OSCC, 39.5% in leukoplakias and 0% in controls. The highest frequency of mutations was found in exon 5 (46.2%) in OSCC and in exon 6 (23.3%) in leukoplakia. More than one mutation was detected in 26.9% of OSCC and 7% of leukoplakia specimens. At least one mutation was found in 37.5% of T1 OSCC and 100% of T4 OSCC specimens and in 37.1% of the L1 leukoplakia and 100% of L3 leukoplakia specimens.CONCLUSIONS: TP53 mutations could be a useful prognostic indicator in precancerous oral lesions. Although the brush biopsy technique appears simple clinically, further investigations are necessary to specify the implications of genetic analysis.",

keywords = "Biopsy, Carcinoma, Squamous Cell/genetics, Chromosome Deletion, DNA Mutational Analysis, Exons, Female, Genes, p53/genetics, Humans, Leukoplakia, Oral/genetics, Male, Middle Aged, Mouth Mucosa/pathology, Mouth Neoplasms/genetics, Neoplasm Staging, Precancerous Conditions/genetics",

author = "C Scheifele and H Schlechte and G Bethke and Reichart, {P A}",

year = "2002",

month = nov,

day = "1",

doi = "10.1007/s10006-002-0425-0",

language = "Deutsch",

volume = "6",

pages = "410--4",

number = "6",

}

RIS

TY - JOUR

T1 - Nachweis von TP53-Mutationen mittels Exfoliativzytologie (brush biopsy) oraler Leukoplakien

AU - Scheifele, C

AU - Schlechte, H

AU - Bethke, G

AU - Reichart, P A

PY - 2002/11/1

Y1 - 2002/11/1

N2 - OBJECTIVE: The aim of this study was to determine the prevalence of mutations of the tumour suppressor gene TP53 in oral leukoplakias.MATERIAL AND METHOD: Brush biopsy specimens of 43 oral leukoplakias, 26 oral squamous cell carcinomas (OSCC) for reference, and the oral mucosa of 4 clinically normal volunteers were collected. DNA of the critical exons 5-8 was analysed by temperature gradient gel electrophoresis (TGGE).RESULTS: The prevalence of mutations was 57.7% in OSCC, 39.5% in leukoplakias and 0% in controls. The highest frequency of mutations was found in exon 5 (46.2%) in OSCC and in exon 6 (23.3%) in leukoplakia. More than one mutation was detected in 26.9% of OSCC and 7% of leukoplakia specimens. At least one mutation was found in 37.5% of T1 OSCC and 100% of T4 OSCC specimens and in 37.1% of the L1 leukoplakia and 100% of L3 leukoplakia specimens.CONCLUSIONS: TP53 mutations could be a useful prognostic indicator in precancerous oral lesions. Although the brush biopsy technique appears simple clinically, further investigations are necessary to specify the implications of genetic analysis.

AB - OBJECTIVE: The aim of this study was to determine the prevalence of mutations of the tumour suppressor gene TP53 in oral leukoplakias.MATERIAL AND METHOD: Brush biopsy specimens of 43 oral leukoplakias, 26 oral squamous cell carcinomas (OSCC) for reference, and the oral mucosa of 4 clinically normal volunteers were collected. DNA of the critical exons 5-8 was analysed by temperature gradient gel electrophoresis (TGGE).RESULTS: The prevalence of mutations was 57.7% in OSCC, 39.5% in leukoplakias and 0% in controls. The highest frequency of mutations was found in exon 5 (46.2%) in OSCC and in exon 6 (23.3%) in leukoplakia. More than one mutation was detected in 26.9% of OSCC and 7% of leukoplakia specimens. At least one mutation was found in 37.5% of T1 OSCC and 100% of T4 OSCC specimens and in 37.1% of the L1 leukoplakia and 100% of L3 leukoplakia specimens.CONCLUSIONS: TP53 mutations could be a useful prognostic indicator in precancerous oral lesions. Although the brush biopsy technique appears simple clinically, further investigations are necessary to specify the implications of genetic analysis.

KW - Biopsy

KW - Carcinoma, Squamous Cell/genetics

KW - Chromosome Deletion

KW - DNA Mutational Analysis

KW - Exons

KW - Female

KW - Genes, p53/genetics

KW - Humans

KW - Leukoplakia, Oral/genetics

KW - Male

KW - Middle Aged

KW - Mouth Mucosa/pathology

KW - Mouth Neoplasms/genetics

KW - Neoplasm Staging

KW - Precancerous Conditions/genetics

U2 - 10.1007/s10006-002-0425-0

DO - 10.1007/s10006-002-0425-0

M3 - SCORING: Zeitschriftenaufsatz

C2 - 12447653

VL - 6

SP - 410

EP - 414

IS - 6

ER -